iNKT cells expressing MiNK BCMA-CAR and the clinical reference have been administered to NSG-tg (hIL-15) mice bearing OPM-2 tumors expressing luciferase. Note the partial tumor control of treated mice.
MiNK Presentation SITC 2021
IDENTIFICATION AND CHARACTERIZATION OF AN ALLOGENEIC iNKT-CAR TARGETING BCMA
Marco A. Purbhoo, Burcu Yigit, Darrian Moskowitz, Ayat Alsaraby, Maurice Kirby, Anitha Swarna,
Valeriia Nasonenko, Ilya Mishchenko, Sonia De Munari, Waldo Ortuzar, Koen Van Besien, Don Stevens,
Terese Hammond, Xavier Michelet, Marc van Dijk
November 12, 2021
MiNK developed a novel CAR discovery platform, CARDIS, to allow for more rapid and efficient identification of antigen-specific and biologically potent CAR candidates, as shown with the lead iNKT-CAR candidate targeting BCMA
The CARDIS platform is a 2-stage discovery approach that screens highly diverse scFV libraries followed by selection of extremely potent and safe CARs.
This platform enabled the rapid identification of agenT-F6, MiNK’s allogeneic iNKT-CAR targeting BCMA.
AgenT-F6, iNKT-CAR targeting BCMA, is a highly potent cell therapy product showing cytotoxicity against BCMA expressing tumors cells in vitro and in vivo comparable to the clinical reference.
